Protective effects of polyclonal iTreg induced by IL-2 and TGF-{beta} on a lupus-like syndrome

song guo zheng,juhua wang,david a horwitz
DOI: https://doi.org/10.1096/fasebj.22.1_supplement.1073.12
2008-01-01
The FASEB Journal
Abstract:We have previously reported that the adoptive transfer of antigen‐specific Tregs generated by allogeneic antigen stimulation with TGF‐β prevents the appearance of lupus syndrome induced by injection of DBA/2 mouse spleen cells into (DBA/2 × C57BL/6) F1 mice. Here we show that CD4+CD25‐ cells polyclonally activated ex‐vivo with IL‐2 and TGF‐β (iTreg) have similar beneficial effects in vivo . A single injection of 5 million iTregs prevented increased IgG production, decreased anti‐dsDNA autoantibodies, suppressed proteinuria and prolonged survival of these mice. The treatment with anti‐TGF‐β or ALK5 almost completely blocked the suppressive capacity of iTreg following injection in vivo . Moreover, iTreg suppress CD80 and CD86 expression of dendritic cells (DC). Thus, the protective effect of iTreg is dependent upon TGF‐β and these cells have inhibitory effects on antigen‐presenting DC. The possibility the transferred iTregs can induce T cells in the recipient mice to become iTreg is being explored. Since SLE, a systemic, generalized autoimmune disease, is characterized by impaired production of IL‐2 and TGF‐β, the use of the cytokines ex‐vivo to repair defects in the numbers and functional activity of CD4+CD25+Foxp3+ Treg cells in this disease may have therapeutic potential. Supported by grants from the Arthritis National Research Foundation, Clinical Research Feasibility Fund, James H. Zumberge Faculty Research Innovation Fund, the Arthritis Foundation, ExCell Therapeutics, Nora Eccles Treadwell Foundation, and BD Biosciences.
What problem does this paper attempt to address?